Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative
View Patent ↗The invention concerns pharmaceutical compositions with wound healing or anti-complementary activity, and their uses, said compositions comprising, (1) at least a dextran derivative of general formula DMC a B b Su c , a, b, and c respectively representing the degrees of substitution in the groups MC, B and Su, wherein a≧0.6, b=0 or ≧0.1, and c=0 or ranges widely between 0.1 and 0.5 for a wound healing composition, and a≧0.3, b≧0.1 and c=0 or ranges widely between 0.1 and 0.4 for a composition with anti-complementary activity; (2) and at least a pharmaceutically acceptable carrier, said dextran derivative being present in a single unit dose or at a concentration adapted to the desired wound healing or anti-complementary activity.
1. A pharmaceutical composition which has a healing action and which comprises:
(1) at least one dextran derivative of the general formula DMC a B b Su c in which:
D represents a dextran chain,
MC represents methylcarboxylate groups,
B represents carboxymethylbenzylamide groups,
Su represents sulfate groups,
a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≧0.6, b being ≧0.1 and c being between 0.1 and 0.5,
which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,
(2) and also at least one pharmaceutically acceptable excipient, with said dextran derivative being present at a unit dose of between 0.1 and 50 mg.
2. The pharmaceutical composition as claimed in claim 1 wherein said composition has an action on the healing of the gastric mucosa and is adapted for oral-administration.
3. The pharmaceutical composition as claimed in claim 2 , wherein the unit dose of said dextran derivative is between 1.5 and 10 mg.
4. The pharmaceutical composition as claimed in claim 2 , wherein said composition is present in the form of a gel, a gastric dressing, a syrup or a potable solution.
5. The pharmaceutical composition as claimed in claim 2 , wherein said dextran derivative is enclosed in a gastric juice resistant enclosure.
6. The pharmaceutical composition as claimed in claim 1 , wherein the unit dose of said dextran derivative is between 0.5 and 50 mg.
7. A pharmaceutical composition as claimed in claim 1 , wherein said composition has an action on ocular healing and is present in the form of eye drops or an ophthalmic ointment.
8. The pharmaceutical composition as claimed in claim 7 , wherein the unit dose of said dextran derivative is between 0.1 and 10 mg.
9. A pharmaceutical composition which has an action on skin healing, which is adapted to topical administration and which comprises:
(1) at least one dextran derivative of the general formula DMC a B b Su c in which:
D represents a dextran chain,
MC represents methylcarboxylate groups,
B represents carboxymethylbenzylamide groups,
Su represents sulfate groups,
a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≧0.6, b being ≧0.1 and c being between 0.1 and 0.5,
which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,
(2) and also at least one pharmaceutically acceptable excipient,
with said dextran derivative being present at a concentration of less than 10% by weight/volume.
10. A pharmaceutical composition which is present in the form of an isotonic solution, has an anticomplementary action and which comprises:
(1) at least one dextran derivative of the general formula DMC a B b Su c in which:
D represents a dextran chain,
MC represents methylcarboxylate groups,
B represents carboxymethylbenzylamide groups,
Su represents sulfate groups,
a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≧0.3, b being ≧0.1 and c being between 0.1 and 0.4,
which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,
(2) and also at least one pharmaceutically acceptable excipient,
with said dextran derivative being present at a unit dose of between 5 and 30 mg.
11. A dressing, characterized in that it is soaked with the pharmaceutical composition as claimed in claim 9 .